Foley & Lardner LLP served as legal adviser to MedTech Acquisition Corporation (MedTech), a special purpose acquisition company, in its recently completed merger with TriSalus Life Sciences, Inc. (TriSalus). Following the closing of the merger transaction, MedTech was renamed TriSalus Life Sciences, Inc., and its common stock trades under the ticker symbol “TSLI” on the Nasdaq Global Market.
MedTech Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, with a stated focus on the medical technology industry in the United States and other developed countries.
TriSalus is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. TriSalus’ platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients.
The Foley deal team was led by partner Kevin Shuler and included partners Carrie Long and Julie-Anne Lutfi and associates Shane Callaghan and Britton Grimes.
